SGLT2 Inhibitors Are Your Second-Line Option
For your CKD stage 2 patient with severe albuminuria (756 mg/g) already on an ACEI, add an SGLT2 inhibitor (such as dapagliflozin or empagliflozin) as your second medication to prevent further kidney damage. This represents the strongest evidence-based intervention after RAAS blockade for kidney protection 1, 2.
Why SGLT2 Inhibitors Come First
Your patient meets clear criteria for SGLT2 inhibitor therapy:
- Albuminuria >200 mg/g (yours is 756 mg/g) - well above the threshold
- eGFR ≥20 ml/min/1.73 m² - CKD stage 2 qualifies
- Already on RAAS inhibition - the foundation is established
The 2024 KDIGO guidelines provide a 1A recommendation (highest strength) for SGLT2 inhibitors in adults with CKD when eGFR ≥20 and ACR ≥200 mg/g, regardless of diabetes status 1. The 2024 BMJ guideline reinforces this across all CKD risk strata 2.
Practical Implementation
Start with:
- Dapagliflozin 10 mg daily, OR
- Empagliflozin 10 mg daily
Key monitoring points:
- Continue the SGLT2i even if eGFR drops initially (expected reversible decrease) 1
- Withhold during prolonged fasting, surgery, or critical illness (ketosis risk) 1
- Once started, continue until dialysis initiation unless not tolerated 1
- No need to alter your routine CKD monitoring frequency 1
Third-Line Options (If Additional Therapy Needed)
If blood pressure remains uncontrolled or you need additional kidney protection:
1. Thiazide or thiazide-like diuretic (preferred third agent)
- Chlorthalidone shows efficacy even in stage 4 CKD 3
- Superior outcomes compared to calcium channel blockers or beta-blockers when added to ACEI/ARB 4
2. Non-steroidal mineralocorticoid receptor antagonist (Finerenone)
- Consider if patient has diabetes with ACR >30 mg/g and eGFR >25 5
- Reduces both CKD progression and cardiovascular events 6, 7
- Lower hyperkalemia risk than spironolactone 3
3. Calcium channel blocker (long-acting dihydropyridine)
- Reasonable option but associated with higher cardiovascular and kidney event risk compared to thiazides when added to RAAS blockade 4
Common Pitfalls to Avoid
- Don't wait for diabetes diagnosis - SGLT2 inhibitors benefit non-diabetic CKD patients equally 1, 2
- Don't stop SGLT2i for initial eGFR dip - this is expected and not harmful 1
- Don't use beta-blockers or loop diuretics as routine second agents - associated with worse kidney and cardiovascular outcomes unless specific indication exists (heart failure, volume overload) 4
- Don't forget the UTI history - ensure adequate treatment and consider prophylaxis if recurrent, as SGLT2 inhibitors may slightly increase genital infection risk (not UTI risk)
The Evidence Hierarchy
The recommendation prioritizes SGLT2 inhibitors because recent large trials demonstrate kidney protection independent of glucose-lowering effects 1, 2, 6. Multiple medication classes now show complementary mechanisms: RAAS blockade reduces glomerular pressure, SGLT2 inhibitors reduce hyperfiltration and provide metabolic benefits, and MRAs reduce inflammation and fibrosis 8. Your patient's severe albuminuria makes combination therapy essential, not optional.